Expert Reviews ReDOS Trial Results in mCRC
Tanios Bekaii-Saab, MD, professor of medicine at the Mayo Clinic, discusses results of the ReDOS trial. In the trial, investigators compared 2 arms with different dosing strategies for regorafenib in patients with metastatic colorectal cancer.
Tanios Bekaii-Saab, MD, professor of medicine at the Mayo Clinic, discusses results of the ReDOS trial. In the trial, investigators compared 2 arms with different dosing strategies for regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Investigators gave 1 arm a dose escalation of regorafenib from 80 mg in the first week to 120 mg in the second week, followed by another escalation in the third week to the standard dose of 160 mg. The other arm received the standard dose of 160 mg. This was a positive trial as the investigators’ primary endpoint was reached.
There was a statistically significant difference between the 2 arms, suggesting the escalation dose was superior to the standard.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
